NeuroPace cuts 2026 revenue guide and falls on three downgrades

NeuroPace reduced its 2026 revenue forecast to $91M-$92M from $99.5M-$101.5M, leading to three downgrades. Health Care sector saw high activity but modest gains, with XLV up 2.21%. Larimar and Altimmune insiders made purchases, and InspireMD priced a $37.5M offering.

Original reporting
Published Nov 14, 2026, 2:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 15, 2026, 10:06 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$NPCE
Bearish
high confidence
Mentioned
$NPCE
Relevance
8/10
AlphAI data visualization · based on quantisnow.com
Decision brief

The 30-second read

$NPCEBearishHigh
01

Why it matters

The guidance cut and downgrades triggered a near‑48% price drop, indicating heightened risk for the stock and potential spill‑over to other small‑cap med‑tech names.

02

Market read

The article highlights a significant price move for NPCE driven by a fresh guidance cut and multiple downgrades, making it a high‑impact, actionable event for traders.

03

What to watch

The net loss narrowed and adjusted EBITDA turned positive, which may soften the downside if investors focus on profitability improvement.

Relevance 8/10Novelty 8/10Timing: after-hours Friday

Background

NeuroPace is a niche epilepsy device maker listed on NASDAQ. The company reported Q3 results, trimmed its full‑year revenue outlook, and was downgraded by three brokerages.

Company-level read

Ticker impact

$NPCEBearishHigh confidence
Context

NeuroPace cut its 2026 revenue guidance to $91M‑$92M and was hit with three downgrades, sending the stock down about 48% in Friday's session.

Expected impact

likely continued downside as investors price in lower revenue expectations

Evidence & confidence

The revenue range was reduced by roughly $9M and three broker houses downgraded the stock, causing a sharp intraday drop; no offsetting positive catalyst is present.

Market effects

Health Care sector may see modest drag as the most active small‑cap med‑tech name posted a sharp decline.

U.S. small‑cap and biotech investors likely to reassess exposure to similar neuro‑technology firms.

Limited to U.S. markets; no broader macro impact.

Counterpoint

If the IGE indication proceeds on schedule, the revenue shortfall could be temporary, offering a buying opportunity at lower levels.

Key entities

  • NeuroPace

    NASDAQ‑listed epilepsy device maker (ticker NPCE).

  • Wells Fargo

    Downgraded NPCE to Equal Weight.

  • Leerink Partners

    Downgraded NPCE to Market Perform.

  • JPMorgan

    Downgraded NPCE to Neutral.

Related articles

$NPCEHigh

Why is NeuroPace stock plummeting 40% today?

NeuroPace (NPCE) stock fell 38.3% to $7.42 after reporting Q3 2026 revenue of $23.1M, missing estimates of $27.1M. The company cut its full-year 2026 revenue outlook to $91–92M from $99.5–101.5M, citing sales force disruptions. Leerink downgraded NPCE to Market Perform with a $7 target, while KeyBanc reduced its target to $14. Insider selling and a rate-sensitive macro environment added to the decline.

$NPCEMed

NeuroPace (NPCE) Q3 2026 Earnings Call Transcript

NeuroPace reported Q3 2026 revenue of $23.1M, missing expectations. CEO Joel Becker attributed the shortfall to transient issues, including account-specific operational challenges and sales team transitions. The company revised full-year revenue guidance to $91M-$92M and expects 15% core RNS revenue growth in 2027, accelerating to 20% by year-end. CMS increased the hospital outpatient payment rate for RNS replacement procedures by 11% for 2027.

$NPCEMed

What NeuroPace (NPCE) Said on Its Q3 Earnings Call

NeuroPace (NPCE) reduced its 2026 revenue guidance to $91M-$92M from $99.5M-$101.5M, citing delays at large accounts. Q4 procedure volumes show recovery signs. Adjusted gross margin forecast raised to 83%-83.5%, while operating expenses lowered to $85M-$86M. 2027 RNS revenue growth expected at 15%. FDA submissions for IGE and Remote Care feature are planned.

$NPCEMed

NeuroPace Reports Third Quarter 2026 Financial Results and Provides Revised Full Year Guidance

NeuroPace Inc (NPCE) filed an SEC Form 8-K — Results of Operations and Financial Condition. NeuroPace Reports Third Quarter 2026 Financial Results and Provides Revised Full Year Guidance Q3 2026 total revenue of $23.1 million, including $22.9 million in RNS revenue representing 1% growth Revises full year 2026 revenue guidance to $91 million to $92 million; focused on i